FDA Reviews Precision Drugs Faster, With Less Evidence Than Other Drugs

By David Roza / May 21, 2018 at 3:39 PM
Academic researchers found FDA has approved precision medicines 1.7 years faster on average than nonprecision medicine and with substantially less premarket evidence, which they cautioned could expose patients to unknown risks and uncertain benefits. While the decreased review time speeds up marketing and lowers development costs, it also necessitates waiting for years to collect postmarket data to glean potential adverse events, the researchers concluded in a May Health Affair s article. FDA has approved a handful of drugs in the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.